fabry2009

11/16

2633) Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation. 2004; 110: 1047-1053.34) Linthorst GE, Hollak CE, Korevaar JC, Van Manen JG, Aerts JM. Boeschoten EW alpha-Galactosidase A defi ciency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease. Nephrol Dial Transplant. 2003; 18: 1581-1584.35) Tanaka M, Ohashi T, Kobayashi M, Eto Y, Miyamura N, Nishida K, Araki E, Itoh K, Matsushita K, Hara M, Kuwahara K, Nakano T, Yasumoto N, Nonoguchi H, Tomita K. Identifi cation of Fabry's disease by the screening of alphagalactosidase A activity in male and female hemodialysis patients. Clin Nephrol. 2005; 64: 281-287.36) Ichinose M, Nakayama M, Ohashi T, Utsunomiya Y, Kobayashi M, Eto Y. Signifi cance of screening for Fabry disease among male dialysis patients. Clin Exp Nephrol. 2005; 9: 228-232.37) Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtlander T, Auinger M, Pagliardini S, Spada M, Demmelbauer K, Lorenz M, Hauser AC, Kofl er HJ, Lhotta K, Neyer U, Pronai W, Wallner M, Wieser C, Wiesholzer M, Zodl H, Fodinger M, Sunder-Plassmann G. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol. 2004; 15: 1323-1329.38) Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, Breunig F, Charrow J, Germain DP, Nicholls K, Banikazemi M. Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007; 30: 184-192.39) Kobayashi M, Ohashi T, Sakuma M, Ida H, Eto Y. Clinical manifestations and natural history of Japanese heterozygous females with Fabry disease. J Inherit Metab Dis. 2008; 31: Jan 21. [Epub ahead of print]40) Kitagawa T, et al. Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes. Pediatr Nephrol. 2008; 23(9): 1461-1471.41) Kitagawa T, et al. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry. Mol Genet Metab. 2005; 85: 196-202.42) Tondel C, et al. Renal Biopsy Findings in children and Adolescents with Fabry disease and Minimal Albumiuria. Am J Kidney Dis. 2008; 51: 767-776.43) Schiff mann R, Kopp JB, Austin HA, Sabnis Sharda, Moore DF, Weibel Thais, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease. JAMA. 2001; 285: 2743-2749.44) Wilcox WR, Banikazemi M, Guff on N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP. Long-term safety and effi cacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet. 2004; 75: 65-74.45) Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: Result of a phase IIIB study. J Inherit Metab Dis. 2003; 26: 617-627.46) Eng CM, Guff on N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ. Safety and effi cacy of recombinant human α-galactosidase A replacement therapy in Fabry’s disease. N Engl J Med. 2001; 345: 9-16.47) Waldek S. PR interval and the response to enzyme-replacement therapy for Fabry’s disease. N Engl J Med. 2003; 348: 1186-1189.48) Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: A prospective strain rate imaging study. Circulation. 2003; 108: 1299-1301.49) Spinelli L, Pisani A, Sabbatini M, Petretta M, Andreucci MV, Procaccini D, Lo Surdo N, Federico S, Cianciaruso B. Enzyme replacement therapy with agalsidase ? improves cardiac involvement in Fabry’s disease. Clin Genet. 2004; 66: 158-165.50) Beck M, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A. Fabry disease: overall eff ects of agalsidase alfa treatment. Eur J Clin Invest. 2004; 34: 838-844.51) Beer M, Weidemann F, Breunig F, Knoll A, Koeppe S, Machann W, Hahn D, Wanner C, Strotmann J, Sandstede J. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry’s cardiomyopathy. Am J Cardiol. 2006; 67: 1515-1518.52) Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C. Clinical benefi t of enzyme replacement therapy in Fabry disease. Kidney Int. 2006; 69: 1216-1221.53) Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB. Eff ects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart. 2008; 94: 153-158.54) Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Störk S, Voelker W, Ertl G, Wanner C, Strotmann J. Long-term eff ects of enzyme replacement therapy on Fabry cardiomyopathy: Evidence for a better outcome with early treatment. Circulation. 2009; 119: 524-529.55) Schiff mann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001; 285: 2743-2749.56) Morimoto S, Sugiura A, Iwase M, Kudo N, Hiramitsu S, Uemura A, Ohtsuki M, Kato S, Kato Y, Hishida H. Relief of left ventricular outfl ow obstruction by cibenzoline in a patient with Fabry’s disease: a case report. Angiology. 2006; 57: 241-245.57) Magage S, Linhart A, Bultas J, Vojacek J, Mates M, Palecek T, Popelova J, Tintera J, Aschermann M, Goldman ME, Desnick RJ. Fabry disease: percutaneous transluminal septal myocardial ablation markedly improved symptomatic left ventricular hypertrophy and outfl ow tract obstruction in a classically aff ected male. Echocardiography. 2005; 22: 333-339.

※このページを正しく表示するにはFlashPlayer9以上が必要です